Cargando…
Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy
Objectives. To evaluate the efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) who are refractory to conventional immunosuppressive therapy. Methods. Eligible patients received rituximab at a dose of 1,000 mg at days 1, 15, 169, and...
Autores principales: | Tanaka, Yoshiya, Takeuchi, Tsutomu, Miyasaka, Nobuyuki, Sumida, Takayuki, Mimori, Tsuneyo, Koike, Takao, Endo, Kazuhiro, Mashino, Naomi, Yamamoto, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732415/ https://www.ncbi.nlm.nih.gov/pubmed/26054418 http://dx.doi.org/10.3109/14397595.2015.1060665 |
Ejemplares similares
-
Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis
por: Oba, Koji, et al.
Publicado: (2017) -
Rituximab for treatment of severe lupus nephritis
por: Baskin, E, et al.
Publicado: (2008) -
Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis
por: Suh, Chang-Hee
Publicado: (2022) -
Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies
por: Petricca, Luca, et al.
Publicado: (2020) -
Terbinafine Induced Lupus Erythematosus With Progression to Lupus Nephritis
por: Hindosh, Naif, et al.
Publicado: (2022)